Reverse epidemiology of lipid-death associations in a cohort of end-stage renal disease patients

Nephron - Clinical Practice

Volumn 119, Issue 3, 2011, Pages

  Bowden, Rodney G ^a,b   La Bounty, Paul ^b   Shelmadine, Brian ^b   Beaujean, A Alexander ^a   Wilson, Ronald L ^b   Hebert, Stuart ^c  

^a BAYLOR UNIVERSITY   (United States)

^b Department of Health Human Performance and Recreation ^*

^c UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Cardiovascular disease; Dyslipidemia; End stage renal disease; Hypercholesterolemia; LDL cholesterol; Lipids

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; CHOLESTEROL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; ARTICLE; CARDIOVASCULAR DISEASE; CAUSE OF DEATH; CHOLESTEROL BLOOD LEVEL; COHORT ANALYSIS; DIALYSIS; DYSLIPIDEMIA; FEMALE; HAZARD RATIO; HUMAN; HYPERCHOLESTEROLEMIA; KIDNEY FAILURE; LINEAR REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MORTALITY; PREDICTION; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; RISK FACTOR; SURVIVOR;

AGED; ANALYSIS OF VARIANCE; CHOLESTEROL; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CHOLESTEROL, VLDL; FEMALE; HUMANS; HYPERCHOLESTEROLEMIA; KIDNEY FAILURE, CHRONIC; LINEAR MODELS; MALE; MIDDLE AGED; PARTICLE SIZE; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; TRIGLYCERIDES;

EID: 81155158667     PISSN: None     EISSN: 16602110     Source Type: Journal    
DOI: 10.1159/000329509     Document Type: Article

References (34)

1. Junyent M, Martínez M, Borràs M, et al: Predicting cardiovascular disease morbidity and mortality in chronic kidney disease in Spain. The rationale and design of NEFRONA: a prospective, multicenter, observational cohort study. BMC Nephrol 2010; 11: 14.
2. Tsirpanlis G, Boufidou F, Zoga M: Low cholesterol along with inflammation predicts morbidity and mortality in hemodialysis patients. Hemodial Int 2009; 13: 197-204.
3. Chavalitdhamrong D, Danovitch GM, Bunnapradist S: Is there a reversal of reverse epidemiology in renal transplant recipients? Semin Dial 2007; 20: 544-548.
4. Nanayakkara PWB, Gaillard CAJM: Vascular disease and chronic renal failure: new insights. Neth J Med 2010; 68: 5-14.
5. Sagheb MM, Ostoven MA, Sohrabi Z, et al: Hyperhomocysteinemia and cardiovascular risk in hemodialysis patients. Saudi J Kidney Dis Transpl 2010; 21: 863-866.
6. US Renal Data System: Excerpts from the USRDS 2005 Annual Data Report: Atlas of End-Stage Renal Disease in the United States, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases. Am J Kidney Dis 2006; 47(suppl 1):1-286.
7. Kilpatrick RD, McAllister CJ, Kovesdy CP, et al: Association between serum lipids and survival in hemodialysis patients and impact of race. J Am Soc Nephrol 2007; 18: 293-303. (Pubitemid 46053442)
8. Chmielewski M, Carrero JJ, Nordfors L, et al: Lipid disorders in chronic kidney disease: reverse epidemiology and therapeutic approach. J Nephrol 2008; 21: 635-644.
9. Dungan KM, Guster T, DeWalt D, Buse JB: A comparison of lipid and lipoprotein measurement in the fasting and nonfasting states in patients with type 2 diabetes. Curr Med Res Opin 2007; 23: 2689-2695. (Pubitemid 350147853)
10. Bowden RG, Griggs J, Wilson RL, Gentile M: Cholesterol values are poor markers of disease risk in a chronic disease population. Clin Lipidol 2009; 4: 545-551.
11. Kovesdy CP, Anderson JE: Reverse epidemiology in patients with chronic kidney disease who are not yet on dialysis. Semin Dial 2007; 20: 566-569.
12. Liu Y, Coresh J, Eustace JA, et al: Association between cholesterol level and mortality in dialysis patients: role of inflammation and malnutrition. JAMA 2004; 291: 451-459. (Pubitemid 38129749)
13. Bowden RG, Wilson RL: Malnutrition, inflammation and lipids in a cohort of dialysis patients. Postgrad Med 2010; 122: 196-202.
14. Bowden RG, Hebert S, Wilson R, et al: Comparison of lipid measures and risk stratification among end-stage renal disease patients. J Nephrol 2007; 21: 212-218. (Pubitemid 47072405)
15. Diepeveen SHA, Wetzels JFM, Bilo HJG, van Tits LGH, Stalenhoef AFH: Cholesterol in end-stage renal disease: the good, the bad or the ugly? Neth J Med 2008; 66: 51-63.
16. Balakrishnan VS, Rao M: Genetics and reverse epidemiology among patients on chronic hemodialysis. Semin Dial 2007; 20: 570-576.
17. Nurmohamed SA, Nubé MJ: Reverse epidemiology: paradoxical observations in haemodialysis patients. Neth J Med 2005; 63: 376-381. (Pubitemid 41723235)
18. Kalantar-Zadeh K: Recent advances in understanding the malnutrition-inflammation cachexia syndrome in chronic kidney disease patients: what is next? Semin Dial 2005; 18: 365-369. (Pubitemid 41545870)
19. Kalantar-Zadeh K, Block G, Humphreys MH, McAllister CJ, Kopple JD: A low, rather than a high, total plasma homocysteine is an indicator of poor outcome in hemodialysis patients. J Am Soc Nephrol 2004; 15: 442-453. (Pubitemid 38140786)
20. Curtis JP, Selter JG, Wang Y, et al: The obesity paradox: body mass index and outcomes in patients with heart failure. Arch Intern Med 2005; 165: 55-61. (Pubitemid 40096082)
21. Cano NJ, Pichard C, Roth H, et al: C-reactive protein and body mass index predict outcome in end-stage respiratory failure. Chest 2004; 126: 540-546. (Pubitemid 39093441)
22. Horwich TB, Fonarow GC: Reverse epidemiology beyond dialysis patients: chronic heart failure, geriatrics, rheumatoid arthritis, COPD, and AIDS. Semin Dial 2007; 20: 549-553.
23. Escalante A, Haas RW, del Rincon I: Paradoxical effect of body mass index on survival in rheumatoid arthritis: role of comorbidity and systemic inflammation. Arch Intern Med 2005; 165: 1624-1629. (Pubitemid 41124157)
24. Bowden RG, Hebert S, Wilson, et al: A cholesterol primer for health professionals. Calif J Health Promotion 2006; 4: 12-21.
25. Soedamah-Muthu SS, Chang YF, Otvos J, Evans RW, Orchard TJ: Lipoprotein subclass measurements by nuclear magnetic resonance spectroscopy improve the prediction of coronary artery disease in type 1 diabetes. A prospective report from the Pittsburgh Epidemiology of Diabetes Complications Study. Diabetologia 2003; 46: 674-682. (Pubitemid 36808187)
26. Kaysen GA, Dubin JA, Muller HG, Mitch WE, Rosales LM, Levin NW: Relationships among inflammation nutrition and physiologic mechanisms establishing albumin levels in hemodialysis patients. Kidney Int 2002; 61: 2240-2249. (Pubitemid 34539342)
27. Guarnieri GF, Moracchiello M, Campanacci L, et al: Lecithin-cholesterol acyltransferase (LCAT) activity in chronic uremia. Kidney Int Suppl 1978; 8:S26-S30.
28. McLeod R, Reeve CE, Frohlich J: Plasma lipoproteins and lecithin: cholesterol acyltransferase distribution in patients on dialysis. Kidney Int 1984; 25: 683-688. (Pubitemid 14079964)
29. Vaziri ND: Dyslipidemia of chronic renal failure: the nature, mechanisms, and potential consequences. Am J Physiol Renal Physiol 2006; 290:F262-F272. (Pubitemid 43724980)
30. Dantoine TF, Debord J, Charmes JP, et al: Decrease of serum paraoxonase activity in chronic renal failure. J Am Soc Nephrol 1988; 9: 2082-2088.
31. Trivedi H, Xiang Q, Klein JP: Risk factors for non-fatal myocardial infarction and cardiac death in incident dialysis patients. Nephrol Dial Transplant 2009; 24: 258-266.
32. Marcovecchio ML, Dalton RN, Prevost AT, et al: Prevalence of abnormal lipid profiles and the relationship with the development of microalbuminuria in adolescents with type I diabetes. Diabetes Care 2009; 32: 658-666.
33. Balakrishnan VS, Rao M: Genetics and reverse epidemiology among patients on chronic hemodialysis. Semin Dial 2007; 20: 570-576.
34. Porazko T, Kuzniar J, Kusztal M, et al: IL-18 is involved in vascular injury in end-stage renal disease patients. Nephrol Dial Transplant 2009; 24: 589-596.